BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/9/2022 7:17:56 AM | Browse: 671 | Download: 1579
 |
Received |
|
2022-01-22 13:02 |
|
Peer-Review Started |
|
2022-01-22 13:04 |
|
First Decision by Editorial Office Director |
|
2022-03-16 01:36 |
|
Return for Revision |
|
2022-03-16 01:36 |
|
Revised |
|
2022-03-21 14:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-04-06 02:11 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-04-09 18:27 |
|
Articles in Press |
|
2022-04-09 18:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-11 12:24 |
|
Publish the Manuscript Online |
|
2022-06-09 07:17 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fei Xu, Meng-Ling Xia, Hui-Yun Pan, Jiong-Wei Pan and Yi-Hong Shen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yi-Hong Shen, MD, Chief Doctor, Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. drsyh@zju.edu.cn |
| Key Words |
Next-generation sequencing; DelE709_T710insD; Non-small-cell lung cancer; Dacomitinib; Uncommon EGFR mutation; Case report |
| Core Tip |
DelE709_T710insD is an extremely rare complex in-frame deletion mutation in exon 18 and accounts for only 0.11% of epidermal growth factor receptor mutations. The development of next-generation sequencing enabled the more identification of rare variants. Our case is the first report describing the clinical efficacy of dacomitinib for delE709_T710insD and achieved a progression-free survival of 7.0 mo. More patients with the rare variants may benefit from dacomitinib targeted therapy based on our study. |
| Publish Date |
2022-06-09 07:17 |
| Citation |
Xu F, Xia ML, Pan HY, Pan JW, Shen YH. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report. World J Clin Cases 2022; 10(17): 5916-5922
|
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i17/5916.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i17.5916 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
